Moderna, Inc. (NASDAQ:MRNA - Get Free Report) CFO James M. Mock sold 705 shares of the stock in a transaction on Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the sale, the chief financial officer now directly owns 5,048 shares in the company, valued at $514,542.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Moderna Price Performance
Shares of NASDAQ MRNA opened at $111.60 on Wednesday. The firm has a 50-day simple moving average of $99.43 and a 200-day simple moving average of $93.33. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $42.73 billion, a price-to-earnings ratio of -8.99 and a beta of 1.62. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $163.24.
Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $1.33. The company had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. Moderna's quarterly revenue was down 44.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.61 EPS. On average, equities analysts predict that Moderna, Inc. will post -7.48 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Moderna
Healthcare Takes A Big Step Forward With The Help Of AI
From The Bull Report | Ad
The average doctor can diagnose an illness correctly 50-90% of the time.
But one innovative company's medical AI gets it right 92%+.
Click here to see why this small company is trusted by the Mayo Clinic
A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of Moderna by 22.6% in the 4th quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company's stock worth $3,372,058,000 after acquiring an additional 6,248,623 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Moderna by 28.8% in the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company's stock valued at $718,584,000 after purchasing an additional 1,614,460 shares during the period. Geode Capital Management LLC increased its position in Moderna by 1.3% during the first quarter. Geode Capital Management LLC now owns 6,244,957 shares of the company's stock worth $957,063,000 after purchasing an additional 77,265 shares during the last quarter. Morgan Stanley raised its stake in Moderna by 19.1% during the fourth quarter. Morgan Stanley now owns 4,187,353 shares of the company's stock worth $752,133,000 after purchasing an additional 670,284 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in Moderna by 77.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company's stock valued at $400,367,000 after purchasing an additional 1,690,341 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.
Analysts Set New Price Targets
A number of research analysts have weighed in on the stock. William Blair reiterated a "market perform" rating on shares of Moderna in a research report on Monday, April 1st. Needham & Company LLC reiterated a "hold" rating on shares of Moderna in a research report on Thursday, March 28th. HSBC reissued a "reduce" rating and issued a $86.00 price objective (up from $75.00) on shares of Moderna in a report on Monday, February 26th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $125.00 target price on shares of Moderna in a research note on Thursday, March 28th. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $125.00 price target on shares of Moderna in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $126.49.
View Our Latest Stock Analysis on MRNA
About Moderna
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
